Shots:
Cytiva and Yoshindo sign a FlexFactory contract to support the establishment of domestic biosimilar drug substance manufacturing in Japan. The investment is partly supported by Japan’s MHLW
Yoshindo plans to supply biosimilars from its Toyama plant starting in 2028, supporting a stable and affordable biologics supply in Japan
Cytiva’s FlexFactory platform uses modular bioprocessing technologies to support faster transition from facility design to GMP…
